Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018–2021) compared to the sorafenib era (2008–2018)

Documenti analoghi

• Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study
  di: Fabio Piscaglia, et al.
  Pubblicazione: (2024)
• Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study
  di: Shusuke Uekusa, et al.
  Pubblicazione: (2024)
• Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL‐6/STAT3 pathway
  di: Wenting Wang, et al.
  Pubblicazione: (2024)
• Re‐evaluating the diagnostic value of α‐fetoprotein for hepatocellular carcinoma in the direct‐acting antiviral era
  di: Yoshinori Takeda, et al.
  Pubblicazione: (2026)
• Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy
  di: Helen M. Johnson, et al.
  Pubblicazione: (2024)